Stocky turns companies like Supernus Pharmaceuticals, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. Supernova suffers from anemic growth (27/100 Compounder Score) and heavy concentration risk: five drugs drive 86% of revenue, with Qelbree alone 49%, while three distributors represent 76% of sales. Strong leadership alignment (78.5/100, likely reflecting founder stability) cannot offset the structural vulnerability of a biotech-dependent revenue model vulnerable to patent cliffs and commercial execution risk.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Supernus Pharmaceuticals, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 30/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Supernus Pharmaceuticals, Inc. (SUPN) at 30/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. Supernova suffers from anemic growth (27/100 Compounder Score) and heavy concentration risk: five drugs drive 86% of revenue, with Qelbree alone 49%, while three distributors represent 76% of sales. Strong leadership alignment (78.5/
SUPN's current Stocky Verdict is 30/100, placing it in the "Avoid" band. This composite combines a 27/100 Compounder score, 79/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Supernus Pharmaceuticals, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Supernus Pharmaceuticals, Inc. scores 79/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Supernus Pharmaceuticals, Inc.'s Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Supernus Pharmaceuticals, Inc..
Sign up free and unlock the full analysis on SUPN — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for SUPN in the app.
